Carvedilol must not be used in patients with: New York Heart Association (NYHA) Class-IV decompensated heart failure requiring intravenous inotropic support; Bronchial asthma; Chronic obstructive pulmonary disease (COPD) with a bronchospastic component; Clinically manifest liver dysfunction; 2nd and 3rd degree AV-block; Severe bradycardia (< 50 bpm); Shock, including cardiogenic shock and hypovolaemic shock; Sick sinus syndrome (including sino-artrial block); Severe hypotension (systolic blood pressure < 85 mmHg).
Hypersensitivity to the drug. Allergic disorder (including asthma and allergic rhinitis) which may suggest a predisposition to bronchospasm);
Carvedilol should not be used during pregnancy or lactation, or in children younger than 18 years.
Pregnancy and nursing mothers: There is no adequate experience with carvedilol in pregnant women. Animal reproduction studies have revealed no teratogenic potential for carvedilol. Beta blockers reduce placental perfusion, which may result in intrauterine fetal death, immature and premature deliveries. In addition, adverse effects (especially hypoglycemia and bradycardia) may occur in the fetus and neonate. There is increased risk of cardiac and pulmonary complications in the neonate in the postnatal period. Therefore, carvedilol should not be used during pregnancy. Carvedilol and/or its metabolites are excreted in breast milk. Therefore, breast-feeding is not recommended during administration of carvedilol.